DraftKings Inc vs Revvity Inc — how do they compare? DraftKings Inc trades at $19.4 (market cap $9.86B), while Revvity Inc trades at $154.86 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Revvity Inc for 12 Days on average.
| DKNG | RVTY | |
|---|---|---|
Market Cap | $9.86B | $16.98B |
Volume | 16,584,596 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $157.36 |
52-Week Low | $18.59 | $82.26 |
Typical Hold Time | 55 Days | 12 Days |
Enterprise Value | $10.80B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.43, down 1.46% on the day and near 52-week lows. The technical picture is bearish with weak moving averages, while fundamentals show strong revenue growth to $6.05B in 2025 but negative profitability metrics. Recent earnings misses and high valuation multiples create headwinds, though analyst sentiment remains overwhelmingly bullish with a $33.13 price target.
The stock faces near-term pressure from technical weakness and earnings volatility, but long-term prospects are supported by market share leadership and prediction platform expansion. Key risks include competitive threats, regulatory uncertainty, and the sustainability of current valuation levels amid profitability challenges.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
Latest headlines on both assets
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →